22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis.
Peking Union Medical College
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.
Aligarh Muslim University
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.
The University of Queensland
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.
Merck
From methylene bridged diindole to carbonyl linked benzimidazoleindole: Development of potent and metabolically stable PCSK9 modulators.
University of Wisconsin-Madison
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
Merck
Novel Cyclic Tetramer Compounds as PCSK9 Inhibitors for Treating Metabolic Disorders.
Lauren Mccallister
Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
University of Wisconsin
Small molecules as inhibitors of PCSK9: Current status and future challenges.
China Pharmaceutical University
O'-(epoxyalkyl)tyrosines and (epoxyalkyl)phenylalanine as irreversible inactivators of serine proteases: synthesis and inhibition mechanism.
State University
Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
Vanderbilt University
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
Bristol-Myers Squibb